Materials
Presentations
Welcoming Remarks
Mitchell Leus, Forum for Collaborative Research
Session I: Working Group Updates
CAM Nomenclature Working Group
Oliver Lenz, Janssen Pharmaceuticals
Stopping Finite Treatment Working Group
Marion Peters, University of California, San Francisco
Patient Advocate Perspective
Maureen Kamischke, Hepatitis B Foundation
Su Wang, Center for Asian Health, Saint Barnabas Medical Center
Session II: HDV Co-Infection Working Group
HDV RNA Assays Writing Group – Paper Outline
Heiner Wedemeyer, Hannover Medical School
Regulatory Perspective on HDV Diagnostics/Endpoints
Maria Ines Garcia, FDA, Center for Devices and Radiological Health
Michael Thomson, FDA, Center for Drug Evaluation and Research
Patient Advocate Perspective
Maureen Kamischke, Hepatitis B Foundation
Su Wang, Center for Asian Health, Saint Barnabas Medical Center
Session III: Biomarkers
Gilead Biomarkers Program
Jeffrey Wallin, Gilead Sciences, Inc
GSK Biomarkers Program
Dickens Theodore, GSK
Biomarkers Project at HBV Forum
Veronica Miller, Forum for Collaborative Research
Doug Mayers, Antios Therapeutics
Session IV: Matching the Mechanism of Action to the HBV Subpopulation Working Group
Working Group Aims and Goals
Jordan Feld, Toronto Centre for Liver Disease
Michael Biermer, Janssen Pharmaceuticals
Drug Development in HBeAg Positive Subpopulations
Patrick Kennedy, Queen Mary University of London
Drug Development in HBeAg Negative Subpopulations
Pietro Lampertico, University of Milan
